You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
MDxHealth will use Ghent's methylation in situ hybridization technology to develop tests for urological cancers.
The firm said that the technologies it has licensed improve PCR and RT-PCR amplification of DNA and RNA.
Laboratoire Cerba was granted the right to develop a tumor expression test based on IntegraGen's proprietary microRNA biomarker.
MBL will use the technology primarily for its diagnostic reagents business.
The technologies monitor patient response to immunotherapies.
Both companies plan to offer the test to researchers and clinicians to help better determine when a patient can be diagnosed with an infectious disease.
The non-exclusive licensing and distribution deal with Evolution Labs makes PolypDx available in five states.
The tests will enable clinicians to diagnose early-stage Alzheimer's disease more accurately by detecting biomarkers in cerebrospinal fluid.
The two firms will have the ability to develop instruments for commercialization within the IVD space.
The firm is developing a sepsis and SIRS diagnostic that combines its own molecule counting technology with Thermo Fisher's procalcitonin assay.